Janssen affiliate Cilag GmbH International entered a worldwide collaboration and license agreement with argenx BVBA and argenx SE focused on the investigational antibody cusatuzumab (ARGX-110) for use in blood cancers. The antibody targets CD70 immune receptors implicated in numerous cancers, including hematological malignancies. The first-in-class antibody is currently in Phase 1/2 clinical trials to evaluate its safety, tolerability and efficacy in the treatment of acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).  According to the company, the deal has a total value of $ 300 million; a separate equity investment by Johnson & Johnson Innovation (JJDC) will be made in argenx SE.